BCMA-Targeted Treatments Boost Responses in Relapsed/Refractory Myeloma

Caroline Seymour
Published: Monday, Mar 16, 2020
Noopur S. Raje, MD, director, Multiple Myeloma Program, Medical Oncology, Massachusetts General Hospital, and professor of medicine, Harvard Medical School

Noopur S. Raje, MD

Preliminary data with BCMA-directed antibody-drug conjugates (ADCs), bispecific T-cell engagers (BiTEs), and CAR T-cell therapy have demonstrated the importance of targeting BCMA in multiple myeloma, according to Noopur S. Raje, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication